Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Hofseth Biocare ASA ( (HOFBF) ) has issued an update.
Hofseth BioCare ASA reported a decline in operating revenues for Q3 2025, attributed to lower commodity prices and a weaker U.S. dollar. Despite the revenue drop, the company achieved significant milestones, including record processing volumes at its Midsund plant, a 200% increase in Human Nutrition B2B sales driven by products like OmeGo® and ProGo®, and a 30% growth in Consumer & Pet Health revenues. These developments, alongside successful clinical studies and product launches, indicate a strategic shift towards high-value specialty ingredients, potentially strengthening HBC’s market position.
More about Hofseth Biocare ASA
Hofseth BioCare ASA is a Norwegian company specializing in consumer and pet health products, focusing on sustainability and optimal utilization of natural resources. It converts salmon industry by-products into health-improving ingredients such as ProGo®, OmeGo®, and CalGo®, which are used for human and pet health. The company emphasizes scientific research and has developed partnerships to explore unique health benefits, including iron metabolism improvement and immune health. HBC is headquartered in Ålesund, Norway, with branches in several international locations and is listed on Oslo Børs.
Average Trading Volume: 97,890
Current Market Cap: NOK776.9M
For detailed information about HOFBF stock, go to TipRanks’ Stock Analysis page.